789 Zarren

platinum 789Final analysis of the phase III KEYNOTE-789 trial evaluating pemetrexedplatinum chemotherapy with or without pembrolizumab in TKI-resistant, EGFR-mutated, metastaticFinal analysis of the phase III KEYNOTE-789 trial evaluating pemetrexedplatinum chemotherapy with or without pembrolizumab in TKI-resistant, EGFR-mutated, metastatic